The University of Kentucky's Sanders-Brown Center on Aging is seeking participants for its clinical trial of an experimental drug that has the potential to prevent Alzheimer's disease.
The A4 Study will recruit 1,000 participants ages 65-85 to test an amyloid antibody that may prevent memory loss caused by Alzheimer's. Amyloid is a protein normally produced in the brain that can build up in older people, forming plaque deposits in the brain. Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer's.
Sanders-Brown is the only center in Kentucky and the only center within 200 miles of Lexington participating in the study.
A4 participant candidates will undergo a series of tests to determine their eligibility, including an imaging test called a PET scan to determine whether they have evidence of amyloid plaque buildup.
Never miss a local story.
The A4 study is just one of many Alzheimer's-related clinical trials being conducted at the Sanders-Brown Center on Aging, according to a release from the center. For more information, contact Sarah Tarrant at (859) 323-1331.